Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
13
CVAC Quote, Financials, Valuation and Earnings
Last price:
$4.31
Seasonality move
:
-17.5%
Day range:
$4.24 - $4.35
52-week range:
$2.48 - $5.72
Dividend yield:
0%
P/E ratio:
6.03x
P/S ratio:
11.97x
P/B ratio:
0.95x
Volume:
474.4K
Avg. volume:
1.6M
1-year change:
44.15%
Market cap:
$970.5M
Revenue:
$578.9M
EPS (TTM):
$0.71
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
EVO
Evotec SE
|
$219.8M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
|
NNNN
Anbio Biotechnology
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$4.31 | $5.31 | $970.5M | 6.03x | $0.00 | 0% | 11.97x |
|
BNTX
BioNTech SE
|
$95.13 | $138.33 | $22.9B | 191.55x | $0.00 | 0% | 6.47x |
|
EVO
Evotec SE
|
$3.1300 | $5.4436 | $1.1B | -- | $0.00 | 0% | 1.34x |
|
IFRX
InflaRx NV
|
$1.14 | $11.24 | $77.2M | -- | $0.00 | 0% | 352.24x |
|
IMTX
Immatics NV
|
$10.37 | $18.75 | $1.3B | 42.21x | $0.00 | 0% | 13.85x |
|
NNNN
Anbio Biotechnology
|
$35.84 | -- | $1.6B | -- | $0.00 | 0% | 171.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
EVO
Evotec SE
|
37.72% | 1.505 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
|
NNNN
Anbio Biotechnology
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
NNNN
Anbio Biotechnology
|
-- | -- | -- | -- | -- | -- |
CureVac NV vs. Competitors
-
Which has Higher Returns CVAC or BNTX?
BioNTech SE has a net margin of -5832.47% compared to CureVac NV's net margin of -1.89%. CureVac NV's return on equity of 20.55% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About CVAC or BNTX?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 23.51%. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 46.94%. Given that BioNTech SE has higher upside potential than CureVac NV, analysts believe BioNTech SE is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 BNTXBioNTech SE14 5 0 -
Is CVAC or BNTX More Risky?
CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock CVAC or BNTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BNTX?
CureVac NV quarterly revenues are $63.3M, which are smaller than BioNTech SE quarterly revenues of $1.8B. CureVac NV's net income of $319.3M is higher than BioNTech SE's net income of -$33.5M. Notably, CureVac NV's price-to-earnings ratio is 6.03x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 11.97x versus 6.47x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV11.97x 6.03x $63.3M $319.3M BNTXBioNTech SE6.47x 191.55x $1.8B -$33.5M
-
Which has Higher Returns CVAC or EVO?
Evotec SE has a net margin of -5832.47% compared to CureVac NV's net margin of -26.29%. CureVac NV's return on equity of 20.55% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About CVAC or EVO?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 23.51%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 74.58%. Given that Evotec SE has higher upside potential than CureVac NV, analysts believe Evotec SE is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 EVOEvotec SE1 0 0 -
Is CVAC or EVO More Risky?
CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.
-
Which is a Better Dividend Stock CVAC or EVO?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or EVO?
CureVac NV quarterly revenues are $63.3M, which are smaller than Evotec SE quarterly revenues of $191.5M. CureVac NV's net income of $319.3M is higher than Evotec SE's net income of -$50.3M. Notably, CureVac NV's price-to-earnings ratio is 6.03x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 11.97x versus 1.34x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV11.97x 6.03x $63.3M $319.3M EVOEvotec SE1.34x -- $191.5M -$50.3M
-
Which has Higher Returns CVAC or IFRX?
InflaRx NV has a net margin of -5832.47% compared to CureVac NV's net margin of -51538.49%. CureVac NV's return on equity of 20.55% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About CVAC or IFRX?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 23.51%. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 886.3%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 IFRXInflaRx NV5 2 0 -
Is CVAC or IFRX More Risky?
CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock CVAC or IFRX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IFRX?
CureVac NV quarterly revenues are $63.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. CureVac NV's net income of $319.3M is higher than InflaRx NV's net income of -$14.3M. Notably, CureVac NV's price-to-earnings ratio is 6.03x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 11.97x versus 352.24x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV11.97x 6.03x $63.3M $319.3M IFRXInflaRx NV352.24x -- $27.8K -$14.3M
-
Which has Higher Returns CVAC or IMTX?
Immatics NV has a net margin of -5832.47% compared to CureVac NV's net margin of -974.45%. CureVac NV's return on equity of 20.55% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About CVAC or IMTX?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 23.51%. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 80.81%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 IMTXImmatics NV9 0 0 -
Is CVAC or IMTX More Risky?
CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock CVAC or IMTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IMTX?
CureVac NV quarterly revenues are $63.3M, which are larger than Immatics NV quarterly revenues of $6.1M. CureVac NV's net income of $319.3M is higher than Immatics NV's net income of -$59.1M. Notably, CureVac NV's price-to-earnings ratio is 6.03x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 11.97x versus 13.85x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV11.97x 6.03x $63.3M $319.3M IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M
-
Which has Higher Returns CVAC or NNNN?
Anbio Biotechnology has a net margin of -5832.47% compared to CureVac NV's net margin of --. CureVac NV's return on equity of 20.55% beat Anbio Biotechnology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B NNNNAnbio Biotechnology-- -- -- -
What do Analysts Say About CVAC or NNNN?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 23.51%. On the other hand Anbio Biotechnology has an analysts' consensus of -- which suggests that it could fall by --. Given that CureVac NV has higher upside potential than Anbio Biotechnology, analysts believe CureVac NV is more attractive than Anbio Biotechnology.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 NNNNAnbio Biotechnology0 0 0 -
Is CVAC or NNNN More Risky?
CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison Anbio Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CVAC or NNNN?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anbio Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Anbio Biotechnology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or NNNN?
CureVac NV quarterly revenues are $63.3M, which are larger than Anbio Biotechnology quarterly revenues of --. CureVac NV's net income of $319.3M is higher than Anbio Biotechnology's net income of --. Notably, CureVac NV's price-to-earnings ratio is 6.03x while Anbio Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 11.97x versus 171.25x for Anbio Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV11.97x 6.03x $63.3M $319.3M NNNNAnbio Biotechnology171.25x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
